Test detail

# Research on mRNA Vaccine-Derived Spike Protein and Blood Clotting/Inflammation ## 1. Research on Spike Protein Vascular Toxicity ### Lei et al. (2021) - *Circulation Research* - **Content**: Demonstrated that spike protein alone (without infection or replication) causes damage to vascular endothelial cells - **Mechanism**: Mitochondrial dysfunction, disruption of ACE2 signaling pathway - **Notable point**: One of the early studies showing toxicity of spike alone rather than the entire virus - **Caveat**: Pseudovirus used, discrepancies from physiological concentrations noted ### Nuovo et al. (2021) - *Annals of Diagnostic Pathology* - Confirmed correlation between spike protein and vascular inflammation in tissues of COVID-19 decedents --- ## 2. Research on Blood Clot Formation Mechanisms ### Effects on Fibrin Aggregation - **Grobbelaar et al. (2021)** (*Bioscience Reports*): S1 subunit of spike protein may promote **microclot** formation - Forms abnormal coagulation structures through interaction with fibrinogen ### Platelet Activation - Reports of spike protein activating platelets through ACE2 and **FcγRIIA receptors** (Ryu et al., 2021) --- ## 3. Research on Adverse Events Following Vaccination ### Myocarditis - **Buergin et al. (2023)** (*European Journal of Heart Failure*): Reports of troponin elevation post-mRNA vaccination (including asymptomatic cases) - CDC and WHO officially recognized myocarditis risk in young males ### VITT (Vaccine-Induced Immune Thrombotic Thrombocytopenia) - Primarily confirmed with adenovirus vector vaccines (AZ, J&J) - **Extremely rare** similar reports with mRNA vaccines ### Spike Protein Persistence in Body - **Ogata et al. (2022)** (*Clinical Infectious Diseases*): S1 protein detected in blood several days after vaccination - **Röltgen et al. (2022)** (*Cell*): Reports of retention in lymph nodes for up to 60 days --- ## 4. Research on Inflammatory Mechanisms | Mechanism | Content | Related Research | |-----------|---------|------------------| | TLR4 activation | Excessive innate immune activation | Shirato & Kizaki (2021) | | NLRP3 inflammasome | Inflammatory cytokine production | Pan et al. (2021) | | ACE2 downregulation | Disruption of renin-angiotensin system | Verdecchia et al. (2020) | | Molecular mimicry | Potential autoimmune response induction | Vojdani et al. (2021) | --- ## 5. Critical Perspectives and Counter-Research ### Research Suggesting Vaccine Risk Lower Than Infection - **Patone et al. (2021)** (*Nature Medicine*): Post-COVID-19 infection myocarditis risk is **significantly higher** than post-vaccine - Most large-scale epidemiological studies do not confirm increased blood clotting in overall vaccinated population ### Methodological Criticism - Many in vitro studies use spike amounts **exceeding physiological concentrations** - Difficulty of extrapolating from cell experiments to humans --- ## 6. Currently Ongoing Research Questions ``` Unresolved issues: ├── Precise production amount and distribution of spike protein in body ├── Impact of individual differences (genetic factors) ├── Presence or absence of long-term tissue accumulation ├── Mechanistic similarities between Long COVID vs. post-vaccine sequelae └── Cumulative effects of repeated vaccinations ``` --- ## Summary and Cautions **Scientifically Confirmed** - Spike protein **theoretically** could influence vascular and coagulation systems - Some adverse reactions (myocarditis, etc.) are officially recognized **Current Mainstream Assessment** - Many studies show vaccine benefits outweigh risks - However, increasing suggestions that stratification by **individual differences, age, sex, and vaccination frequency** is necessary **Important Considerations** > Evaluation requires consideration of research quality, scale, and absence/presence of conflicts of interest. Some research has been noted to have problems with peer review and reproducibility. This is a field requiring continued independent research and transparent data disclosure.

Many studies exist investigating what effects spike protein generated by mRNA vaccines—particularly in COVID-19 vaccines—might have on the body. The following are several major research areas: 1. **Local Effects of Spike Protein**: Spike protein is expressed primarily on cells to trigger immune responses. This generates antibodies, strengthening immunity against future viral infections. Some research investigates the possibility that spike protein itself might trigger temporary localized inflammation. 2. **Risk of Blood Clot Formation**: In very rare cases, blood clots have been reported following mRNA vaccination. These cases are extremely rare, and establishing causal relationships requires further research. Generally, vaccine benefits are considered to outweigh risks. 3. **Research on Immune Responses**: Spike protein generated by mRNA vaccines induces specific immune responses. This confirms effectiveness in preventing severe COVID-19 illness. Temporary inflammatory reactions accompanying immune system activation are expected. 4. **Long-Term Effects**: Because limited time has passed since vaccination began, data accumulation on long-term effects related to spike protein remains ongoing. Long-term monitoring and research continue. Most of these studies examine vaccine safety in detail, and current evidence indicates that mRNA vaccines are safe and effective for the vast majority of people. However, guidelines and recommendations may be updated as new data becomes available.

Regarding the possibility that spike proteins generated in the body through mRNA vaccines cause blood clots and inflammation, concerns and various speculations have been raised since the start of vaccination, and numerous studies have been conducted. Stated in conclusion, **severe thrombosis or inflammation such as myocarditis and pericarditis caused by mRNA vaccines are extremely rare, their mechanisms are complex, and the simple explanation that 'spike protein itself has toxicity that causes these' is not supported**—this is the current scientific consensus. However, research continues to clarify the mechanisms of these adverse reactions. Below, I have summarized the main directions of related research and what is currently known. --- ### 1. Research on Myocarditis and Pericarditis (Inflammation) Myocarditis and pericarditis have been reported as adverse reactions following mRNA vaccination, particularly in young males, making this one of the most researched areas. * **Epidemiological Research (Large-Scale Observational Studies)**: * Using large-scale medical data and registries from countries worldwide (US CDC, European EMA, Israel, Japan, etc.), research has confirmed that the risk of myocarditis and pericarditis slightly increases after mRNA vaccination. Particularly in males from late teens to early twenties, this tends to appear more frequently after the second dose, though most cases are mild and recover. * **Comparison**: The risk of myocarditis following vaccination is far lower than the risk of myocarditis from COVID-19 virus infection. COVID-19 infection shows higher likelihood of severe myocarditis than post-vaccination and also carries higher risk of multi-organ inflammation. * **Mechanism Research (Basic Research)**: * **Immune Response Involvement**: Excessive immune responses to spike protein or production of some autoantibodies may be involved. Immune cells potentially attacking cardiac muscle cells through self-immune-like responses are suspected. * **T Cell Activation**: In individuals with certain HLA types, similar sequences exist between cardiac muscle cells and parts of spike protein; 'molecular mimicry' where T cells activated by vaccination mistakenly attack cardiac cells is suggested (though this remains hypothetical). * **Cytokine Involvement**: Involvement of inflammatory cytokines (proteins mediating immune responses) is being examined, though this differs from the 'cytokine storm' seen in severe COVID-19. * **Direct Impact of Spike Protein Itself**: A small minority of in vitro (test tube) and animal experiments suggest high concentrations of spike protein may directly affect cardiac muscle cells, but these are experiments under conditions vastly different from spike protein production amounts and localization in the body, and human relevance remains unclear. ### 2. Research on Thrombosis The risk of thrombosis following mRNA vaccines differs from the situation with adenovirus vector vaccines (AstraZeneca, Johnson & Johnson), where 'VITT (vaccine-induced immune thrombotic thrombocytopenia)' was confirmed. * **Epidemiological Research (Large-Scale Observational Studies)**: * Large-scale data analysis shows that general thrombosis rates (cerebral venous sinus thrombosis, deep vein thrombosis, etc.) after mRNA vaccination, when compared to background incidence rates in unvaccinated populations, **show no significant increase.** * The specific mechanism-based thrombosis, VITT, reported with adenovirus vector vaccines, has not been confirmed with mRNA vaccines. * **Mechanism Research (Basic Research)**: * **Adenovirus Vector Vaccines and VITT**: The VITT mechanism involves vaccine-contained adenovirus and other components binding to platelet factor 4 (PF4), autoantibodies against this are produced, and these antibodies activate platelets, causing thrombosis. This mechanism does not apply to mRNA vaccines. * **mRNA Vaccines and Spike Protein**: At present, clear evidence that spike protein generated by mRNA vaccines directly activates platelets or damages vascular endothelial cells to promote thrombosis has not been found in large-scale human data or follow-up studies. * A small minority of in vitro studies suggest spike protein binding to vascular endothelial cells and inducing inflammation, though this is frequently discussed in contexts explaining 'virus pathogenicity from COVID-19 infection,' and careful consideration is needed regarding whether spike protein expressed on cell surfaces from vaccine directly contributes to systemic thrombosis formation. ### 3. Research on Body Distribution and Persistence of Spike Protein * **Distribution and Persistence**: Animal experiments and some human studies show spike protein generated by vaccines remains primarily in muscle tissue and lymph nodes at injection sites, degrading and disappearing within days to weeks. The amount circulating systemically is extremely small and temporary. * **Importance of Modification**: Spike protein used in mRNA vaccines differs from natural virus spike protein; portions are modified to promote stable antibody production in the body (e.g., prefusion stabilization). This modification is thought to reduce pathogenicity that natural spike protein might possess (e.g., direct damage to vascular endothelial cells). --- ### Summary and Cautions * **Rarity**: Myocarditis, pericarditis, or thrombosis following mRNA vaccination are exceedingly rare adverse reactions. * **Mechanism Complexity**: Mechanisms of these adverse reactions are complex; many are thought to involve specific aspects of immune responses. The view that 'spike protein has inherent toxicity' is not supported by current research. * **Infection vs. Vaccine Comparison**: COVID-19 virus infection itself causes severe myocarditis, cardiac complications, and thrombosis (especially in severe cases) with far higher probability than post-vaccination adverse reactions. This is clearly demonstrated. * **Benefit-Risk Evaluation**: Most research and public health institutions assess that mRNA vaccine effectiveness in preventing severe COVID-19 far exceeds the risk of these rare adverse reactions. * **Continued Monitoring**: Health agencies in each country (e.g., Japan's Ministry of Health, Labour and Welfare, US CDC/FDA, European EMA) continue collecting and analyzing adverse reaction reports, pursuing safety monitoring and research. You may feel anxious about spike protein being generated in the body, but vaccine-derived spike protein, unlike virus-derived spike protein created through infection, has its amount, localization, and structure rigorously controlled, with significantly different pathogenicity—this point is critical.

**Overview of Research on Spike Protein Generated by mRNA Vaccines** mRNA vaccines (Pfizer/BioNTech, Moderna) make cells temporarily produce SARS-CoV-2 spike protein, inducing immune responses. Production amounts are less than infection, reportedly localized and transient, though research pointing to blood leakage and effects on distant organs exists. Below, I have organized the main research directions (focusing primarily on major studies around 2021-2023). ### 1. Basic Research on Direct Biological Activity of Spike Protein - **Endothelial Dysfunction and Inflammation**: In vitro research suggesting that spike, binding to ACE2 receptor, decreases ACE2 expression and induces inflammatory signaling (NF-κB pathway activation, etc.) in vascular endothelium. - Salk Institute-related Lei et al. (2021) reports and subsequent experiments with vascular endothelial cells. - **Blood Clot Formation Mechanism**: Potential spike promotion of platelet activation and coagulation cascades. - Reports suggesting S1 subunit of spike acts on platelets and endothelial cells, promoting P-selectin expression and von Willebrand factor release (some 2021-2022 literature). - Indications of spike-TLR4 and other pattern recognition receptor interactions amplifying inflammation. ### 2. Research on Spike Detection Post-Vaccination - Ogata et al. (Clinical Infectious Diseases, 2021): Free spike protein detected in plasma several days to one week after vaccination (ng/mL order). - Some research suggesting mRNA and lipid nanoparticles systemically distribute via bloodstream (based on animal experimental data with rats, etc.). - These serve as evidence that 'produced spike does not remain entirely localized'. ### 3. Research and Reports Suggesting Clinical Adverse Effects Correlation - **Myocarditis**: Post-mRNA vaccination myocarditis in young males potentially involves immune responses (particularly T cell responses to spike or autoimmune-like mechanisms), discussed in multiple cohort studies. - **Thrombosis and Microclots**: Unlike adenovirus vector vaccines (AstraZeneca, etc.) with clearly established VITT, mRNA vaccines less explicitly characterized, though case reports and some autopsy examples suggest spike-related vascular complications. - However, large-scale epidemiological data (CDC, EMA, large cohorts) either confirm no significant thrombosis risk increase from mRNA vaccines or classify it as extremely rare. ### 4. Counter-Arguments and Contextual Research - Spike produced by vaccines is small compared to massive production from viral replication during infection; most is membrane-bound or rapidly degraded. - Because spike exposure amount and duration is much greater during natural infection, interpreting vaccine-specific risk emphases requires caution. - Current mainstream views (regulatory authorities, major reviews) largely maintain 'benefits outweigh risks'. ### Important Cautions - Many research findings suggesting concerns mentioned above are in vitro, animal experiments, or small-scale human detection studies; **causal relationship proof** has not been achieved in most cases. - Conversely, vast vaccination data and real-world data have not observed marked increases in severe thrombotic or inflammatory events. - Possibilities that individual baseline conditions (coagulation disorders, autoimmune disease, etc.) alter risk cannot be ruled out. Recommended: Confirming latest meta-analyses and regulatory authority safety monitoring reports. Medical judgment should be discussed with physicians.